Original Source(s)
Related Content
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
Medical Oddities: A needle in an abdominal haystack
A needle goes missing, tea spills secrets, cells age, and dinner serves up a surprise this week.
by Teraya Smith
November 5, 2026
-
6 min
Medical Oddities: Alive, but convinced otherwise
A deadly conviction, healing vanilla, stormy lungs, and a COVID tea party await.
by Teraya Smith
October 15, 2026
-
5 min